Omeros Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,600.00
539.00
13,509.00
41,617.00
64,826.00
29,868
Cost of Goods Sold (COGS) incl. D&A
-
-
1,041.00
1,412.00
1,078.00
993
Gross Income
-
-
12,468.00
40,205.00
63,748.00
28,875
SG&A Expense
51,814.00
70,221.00
83,706.00
94,481.00
107,643.00
141,097
EBIT
50,516.00
70,008.00
71,238.00
54,276.00
43,895.00
112,222
Unusual Expense
12,459.00
863.00
1,315.00
5,595.00
-
12,993
Non Operating Income/Expense
615.00
656.00
1,030.00
945.00
1,444.00
1,781
Interest Expense
2,366.00
3,470.00
3,573.00
7,819.00
11,030.00
16,252
Pretax Income
39,796.00
73,673.00
75,096.00
66,745.00
53,481.00
139,686
Consolidated Net Income
39,796.00
73,673.00
75,096.00
66,745.00
53,481.00
126,757
Net Income
39,796.00
73,673.00
75,096.00
66,745.00
53,481.00
126,757
Net Income After Extraordinaries
39,796.00
73,673.00
75,096.00
66,745.00
53,481.00
126,757
Net Income Available to Common
39,796.00
73,673.00
75,096.00
66,745.00
53,481.00
126,757
EPS (Basic)
1.39
2.22
2.00
1.65
1.17
2.61
Basic Shares Outstanding
28,560.40
33,234.30
37,560.30
40,446.40
45,539.40
48,582.60
EPS (Diluted)
1.39
2.22
2.00
1.65
1.17
2.61
Diluted Shares Outstanding
28,560.40
33,234.30
37,560.30
40,446.40
45,539.40
48,582.60
EBITDA
50,214.00
69,682.00
71,029.00
53,976.00
43,344.00
111,260
Non-Operating Interest Income
12.00
12.00
-
-
-
-

About Omeros

View Profile
Address
The Omeros Building
Seattle Washington 98119
United States
Employees -
Website http://www.omeros.com
Updated 07/08/2019
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.